← Back to all trials
Completed
NCT05098041
A Study of Soticlestat and Rifampin in Healthy Adults
Conditions: Healthy Volunteers
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 15
Sponsor: Takeda
Location: Celerion Belfast
Summary
The main aim of this study is to check how rifampin affects the way soticlestat is processed by the body.
Participants will be required to stay at the study clinic for 18 consecutive days. On the first full day and 15th day, participants will take a single dose of soticlestat. Rifampin will be taken each day starting on the 5th day for 13 consecutive days.
Clinic staff will follow up with each participant about 15 days after the last soticlestat dose to check for any side effects.
Eligibility Criteria
Inclusion criteria:
1. Healthy, adult, male or female of non-childbearing potential, 18-55 years of age, inclusive, at screening.
2. Has body mass index (BMI) greater than or equal to (\>=) 18.0 and less than or equal to (\
Source: ClinicalTrials.gov (NCT05098041). StuddyBuddy aggregates publicly available trial information.
